Court Determines that Kurin Does Not Infringe Magnolia Medical Patent
May 16 2024 - 6:00AM
Business Wire
Kurin, Inc., the inventor and manufacturer of the Kurin® blood
culture collection sets, announced that Chief Judge Connolly of the
U.S. District Court in Delaware issued an opinion in the patent
litigation brought by Magnolia Medical, Inc. finding that “Kurin is
entitled to a judgment of noninfringement of claims 1 and 24 of the
#483 patent as a matter of law.”
“It is rewarding to receive the Court’s determination that Kurin
does not infringe the ‘483 patent and I appreciate the efforts of
our team over the last few years,” said Bob Rogers, CEO of Kurin,
Inc. “From the beginning of this case, we felt confident that we
would prevail and that the lawsuit was a desperate move by a
competitor who could not compete in the marketplace.
“Previously, on Dec. 1, 2023, the US Patent and Trademark Office
issued a final rejection of these same two patent claims. This
opinion by the Court confirms that even if these patent claims were
valid, Kurin does not infringe them. With Magnolia’s case now
largely behind us, we can continue to focus on helping hospitals
improve clinical outcomes and address the financial challenges
posed by blood culture contamination.”
Kurin’s revolutionary 510(k)-cleared approaches to the
contaminated blood culture problem are based on elegantly simple,
intuitive designs that require no additional user steps. Kurin
passively sidelines potential contaminants during blood culture
collection. Contaminated blood cultures are a significant problem,
as roughly one-third of the positive results are wrong, exposing
these patients to unnecessary antibiotics, extending hospital stays
and impacting larger community health issues, such as antimicrobial
resistance and life-threatening C. diff. infections. Kurin Lock and
Kurin Jet give clinicians the tools they need to address these
problems.
About Kurin, Inc.
Kurin, Inc., a certified Minority Business Enterprise (MBE), is
focused on the design, development, manufacture, marketing, and
sale of products that help healthcare providers reduce contaminated
blood cultures. Kurin, manufactured in San Diego, CA, has received
FDA 510(k) market clearance. For more information about Kurin,
visit the website at www.kurin.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516248272/en/
Matt Heindel Kurin, Inc. 858-752-9514 mattheindel@kurin.com